Scholars Central

Conference abstractPublished 8 Sep 2014

Is there a need for an intellectual property (IP) policy in South Africa?

Authors: Makhapa Makhafola

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

South Africa does not have a national IP policy as a result the government departments that deal directly or indirectly with IP approach the system differently. The country?s patent laws are costing the health sector dearly. The health organisations and government are paying heavily to provide life-saving drugs and medical devises to those who can?t afford them. In the absence of the IP policy the government has implemented other intervention strategies that will help with the development of some of the drugs and medical devices locally. One of these strategies is the nanotechnology strategy established through the Department of Science and Technology (DST) to address critical socio-economic challenges facing the country. The DST/ Mintek Nanotechnology Innovation Centre (NIC) was established as one of the major implementing agencies of the national nanotechnology strategy to focus primarily on the social cluster (health and water). The motivation to focus on the health sector is that there is lack of regulations in pricing of the drugs and medical devices. ?Other developing nation like Brazil, India and Argentina have taken steps to build safeguards to protect public health South Africa hasn?t done the same extent?. The World Health Organization has shown that 67% of deaths in South Africa are due to communicable diseases and the cost of drugs and medical devices is controlled by pharmaceutical industries. This paper addresses whether there is a need to have an IP policy in SA and how has the government intervention strategies (like the NIC) progressed in the absence of the IP policy and also the impasse between the government and pharmaceutical industries with regard to the draft IP policy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Pharmaceutical Regulatory Affairs: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutical Regulatory Affairs: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Makhapa Makhafola”